Schwarz Jacob B, Gibbons Sian E, Graham Shelley R, Colbry Norman L, Guzzo Peter R, Le Van-Duc, Vartanian Mark G, Kinsora Jack J, Lotarski Susan M, Li Zheng, Dickerson Melvin R, Su Ti-Zhi, Weber Mark L, El-Kattan Ayman, Thorpe Andrew J, Donevan Sean D, Taylor Charles P, Wustrow David J
Pfizer Global Research and Development, Michigan Laboratories, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA.
J Med Chem. 2005 Apr 21;48(8):3026-35. doi: 10.1021/jm0491086.
As part of a program aimed at generating compounds with affinity for the alpha(2)-delta subunit of voltage-gated calcium channels, several novel beta-amino acids were prepared using an efficient nitroalkane-mediated cyclopropanation as a key step. Depending on the ester that was chosen, the target amino acids could be prepared in as few as three steps. The cyclopropyl amino acids derived from ketones proved to be potent binders of the alpha(2)-delta subunit of voltage-gated calcium channels, but did not interact with the large neutral amino acid system L (leucine) transporter. Anticonvulsant effects were observed in vivo with compound 34 but only after intracerebroventricular (icv) administration, presumably due to inadequate brain concentrations of the drug being achieved following oral dosing. However, pregabalin 1 was active in the DBA/2 model after oral (and icv) dosing, supporting a hypothesis that active transport is a prerequisite for such zwitterionic species to cross the blood-brain barrier.
作为一个旨在生成对电压门控钙通道α(2)-δ亚基具有亲和力的化合物的项目的一部分,使用高效的硝基烷介导的环丙烷化作为关键步骤制备了几种新型β-氨基酸。根据所选的酯,目标氨基酸可以少至三步制备。源自酮的环丙基氨基酸被证明是电压门控钙通道α(2)-δ亚基的有效结合剂,但不与大中性氨基酸系统L(亮氨酸)转运体相互作用。化合物34在体内观察到抗惊厥作用,但仅在脑室内(icv)给药后出现,推测是由于口服给药后脑内药物浓度不足。然而,普瑞巴林1在口服(和icv)给药后在DBA/2模型中具有活性,支持了主动转运是此类两性离子物质穿过血脑屏障的先决条件这一假设。